



Medicines & Healthcare products
Regulatory Agency



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms N Boota
UNIVERSITY OF WARWICK
WARWICK CLINICAL TRIALS UNIT, WARWICK MEDICAL SCHOOL
GIBBET HILL ROAD
COVENTRY
CV4 7AL
UNITED KINGDOM

20/12/2018

Dear Ms N Boota

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference: 16719/0231/001-0003
Eudract Number: 2017-001785-14
Product: Landiolol hydrochloride 300 mg lyophilised powder
Protocol number: STRESS-L
Substantial Amendment Code Number: Code Number: SA_07
Version:
Date: 2018/11/05

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 30/11/2018.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**